Product Description: Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulin G1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical. WHO Drug Information, Vol. 38 , No. 4, 2024.
CAS Number: 2996105-98-5
Molecular Weight: N/A
Research Area: Neurological Disease
Target: TGF-β Receptor